Shares of Omeros Corporation (OMER) are climbing more than 5% Thursday morning after the company announced agreement to sell Omeros' FDA-approved product, Omidria to Rayner Surgical Group Limited in a transaction valued more than $1 billion.
Omeros' Omidria (phenylephrine and ketorolac intraocular solution) is marketed in the U.S. for use during cataract surgery or intraocular lens replacement and to reduce postoperative ocular pain.
The deal includes an upfront payment of $125 million and $200 million on achieving a commercial milestone.
Rayner is expected to pay Omeros royalties on both U.S. and ex-U.S. net sales of Omidria. In the U.S., the royalty rate will be 50 percent of U.S. net sales until the earlier of either January 1, 2025 or payment of the $200-million commercial milestone, after which Omeros will receive royalties of 30 percent of U.S. net sales for the life of Omidria's U.S. patent estate. Outside of the U.S., Omeros will receive a 15-percent royalty rate on Omidria net sales throughout the applicable patent life, the company said.
OMER is at $7.18 currently. It has traded in the range of $5.45- $23.85 in the last one year.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.